1467 related articles for article (PubMed ID: 17462723)
21. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease.
van Trommel NE; Massuger LF; Schijf CP; ten Kate-Booij MJ; Sweep FC; Thomas CM
J Clin Oncol; 2006 Jan; 24(1):52-8. PubMed ID: 16382113
[TBL] [Abstract][Full Text] [Related]
22. Persistent gestational trophoblastic tumour with partial hydatidiform mole as the antecedent pregnancy.
Chen RJ; Huang SC; Chow SN; Hsieh CY; Hsu HC
Br J Obstet Gynaecol; 1994 Apr; 101(4):330-4. PubMed ID: 8199080
[TBL] [Abstract][Full Text] [Related]
23. Comparison of human chorionic gonadotropin +beta and invasive trophoblast antigen disappearance rates in serum after evacuation of molar pregnancy.
Van Trommel NE; Sweep FC; Ross HA; Massuger LF; Thomas CM
Int J Mol Med; 2006 Oct; 18(4):705-11. PubMed ID: 16964426
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of pregnancy-specific beta glycoprotein, human placental lactogen and beta-human chorionic gonadotropin in the serum of patients with trophoblastic diseases].
Zhang WY
Zhonghua Yi Xue Za Zhi; 1989 Apr; 69(4):206-8, 16. PubMed ID: 2476204
[TBL] [Abstract][Full Text] [Related]
25. [The serum concentration of specific beta 1-glycoprotein in trophoblastic disease].
Radikov N
Akush Ginekol (Sofiia); 1989; 28(2):15-9. PubMed ID: 2548413
[TBL] [Abstract][Full Text] [Related]
26. Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles.
Lavie I; Rao GG; Castrillon DH; Miller DS; Schorge JO
Am J Obstet Gynecol; 2005 May; 192(5):1362-4. PubMed ID: 15902109
[TBL] [Abstract][Full Text] [Related]
27. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
[TBL] [Abstract][Full Text] [Related]
28. Gestational trophoblastic diseases - clinical guidelines for diagnosis, treatment, follow-up, and counselling.
Niemann I; Vejerslev LO; Frøding L; Blaakær J; Maroun LL; Hansen ES; Grove A; Lund H; Havsteen H; Sunde L
Dan Med J; 2015 Nov; 62(11):A5082. PubMed ID: 26522484
[TBL] [Abstract][Full Text] [Related]
29. Predictors of persistent disease in women with complete hydatidiform mole.
Ayhan A; Tuncer ZS; Halilzade H; Küçükali T
J Reprod Med; 1996 Aug; 41(8):591-4. PubMed ID: 8866387
[TBL] [Abstract][Full Text] [Related]
30. [Radioimmunoassay of beta sub unit HCG following hydatidiform mole or chorionic carcinoma (author's transl)].
Tscherne G; Pürstner P
Geburtshilfe Frauenheilkd; 1979 Aug; 39(8):704-8. PubMed ID: 478273
[TBL] [Abstract][Full Text] [Related]
31. Gestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results.
Cole LA; Khanlian SA; Giddings A; Butler SA; Muller CY; Hammond C; Kohorn E
Gynecol Oncol; 2006 Aug; 102(2):165-72. PubMed ID: 16631243
[TBL] [Abstract][Full Text] [Related]
32. Serum relaxin in patients with hydatidiform mole.
Seki K; Uesato T; Tabei T; Kato K
Obstet Gynecol; 1986 Mar; 67(3):381-3. PubMed ID: 3945450
[TBL] [Abstract][Full Text] [Related]
33. Serum testosterone and dihydrotestosterone in patients with trophoblastic disease.
Dawood MY; Saxena BB
Obstet Gynecol; 1976 Jun; 47(6):684-8. PubMed ID: 180465
[TBL] [Abstract][Full Text] [Related]
34. Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve.
van Cromvoirt SM; Thomas CM; Quinn MA; McNally OM; Bekkers RL
Gynecol Oncol; 2014 Jun; 133(3):542-5. PubMed ID: 24631700
[TBL] [Abstract][Full Text] [Related]
35. The hCG assay in the treatment of trophoblastic disease.
Pattillo RA; Hussa RO
J Reprod Med; 1984 Nov; 29(11):802-12. PubMed ID: 6097684
[TBL] [Abstract][Full Text] [Related]
36. Serum granulocyte macrophage colony stimulating factor (GM-CSF) in gestational trophoblastic diseases.
Shaarawy M; el-Shobokshy AS; el-Noury AI
Cytokine; 1995 Feb; 7(2):171-5. PubMed ID: 7540057
[TBL] [Abstract][Full Text] [Related]
37. Epidemiologic features of hydatidiform mole in the Netherlands.
Franke HR; Risse EK; Kenemans P; Vooijs GP; Stolk JG
Obstet Gynecol; 1983 Nov; 62(5):613-6. PubMed ID: 6621952
[TBL] [Abstract][Full Text] [Related]
38. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
Gynecol Oncol; 2009 Feb; 112(2):353-7. PubMed ID: 19059633
[TBL] [Abstract][Full Text] [Related]
39. Alpha subunit in gestational trophoblastic disease.
Kohorn EI; Caldwell BV; Cortes JM
Placenta Suppl; 1981; 3():231-40. PubMed ID: 6306644
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios.
van Trommel NE; Sweep FC; Schijf CP; Massuger LF; Thomas CM
Eur J Endocrinol; 2005 Oct; 153(4):565-75. PubMed ID: 16189178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
